Sustained clinical remission for 5 years in severe epidermolysis bullosa acquisita following rituximab infusions
Journal of the European Academy of Dermatology and Venereology · 2024
DOI: 10.1111/jdv.19863 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Ben Koszegi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, St George Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Epidermolysis Bullosa Acquisita, Rituximab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, St George Hospital, Sydney, New South Wales, Australia.
- Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
- Department of Dermatology, Kurume University School of Medicine, Fukuoka, Japan.
ORCID-Profile: Ben Koszegi, Corey Stone, Norito Ishii, Takashi Hashimoto, Dédée F Murrell
Zitieren
APA
Koszegi, B., Stone, C., Ishii, N., Hashimoto, T., & Murrell, D. F. (2024). Sustained clinical remission for 5 years in severe epidermolysis bullosa acquisita following rituximab infusions. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19863
Vancouver
Koszegi B, Stone C, Ishii N, Hashimoto T, Murrell DF. Sustained clinical remission for 5 years in severe epidermolysis bullosa acquisita following rituximab infusions. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19863
BibTeX
@article{Koszegi2024,
author = {Koszegi, Ben and Stone, Corey and Ishii, Norito and Hashimoto, Takashi and Murrell, Dédée F},
title = {Sustained clinical remission for 5 years in severe epidermolysis bullosa acquisita following rituximab infusions},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
doi = {10.1111/jdv.19863}
}
EUVIMED